UNSPSC 51332857: Mesoridazine benzenesulfonate

This classification denotes a dopamine antagonist and antipsychotic agent with the molecular formula C21H26N2OS2.C6H6O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T4G2I958J2, chemically known as 10h-phenothiazine, 10-(2-(1-methyl-2-piperidinyl)ethyl)-2-(methylsulfinyl)-, (+/-)-, monobenzenesulfonate, but more generally known as mesoridazine benzenesulfonate, which bears US NIH Compound Identifier 36207.

European Medicines Agency schedules mesoridazine benzenesulfonate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08786MIG. Most nations, for tariff purposes, schedule mesoridazine benzenesulfonate under HS 29343090. SMILES: CN1CCCCC1CCN2C3CCCCC3SC4C2CC(CC4)[S+](C)[O-].C1CCC(CC1)S(=O)(=O)O.

UNSPSC 51332857 Mesoridazine benzenesulfonate is a Commodity code with minimal concrete market activity aligned to its specific chemical pharmaceutical classification. The recent opportunities tagged under this code show a mismatch between the code's nominal scope—a single antipsychotic medication—and the actual solicitations, which cover broad pharmaceutical procurement programs including naloxone, generic multi-source drugs, and OTC products, as well as exploratory direct-to-manufacturer prescription initiatives. State and local governments do buy pharmaceuticals and medications across wide categories through competitive procurement, but the specific mesoridazine compound does not appear in recent solicitations. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The cooperative purchasing vehicle is particularly active for state and local pharmaceutical procurement, as MMCAP administers contracts on behalf of participating state and local government facilities across multiple jurisdictions.

Recent activity spans Florida, Texas, and Minnesota. Seminole County released an IFB on June 30, 2026, for naloxone and drug deactivation systems—1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023 (note: the due date conflicts with the posted date and likely represents a data error in the source). The Texas HHS Commission posted a Request for Information (RFI) on April 3, 2026, exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements, designed to inform future RFP development. MMCAP issued an RFP due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.), with contracts effective July 1, 2026, and serving state and local government facilities across participating jurisdictions including Oregon. The code shows limited direct procurement activity specific to mesoridazine; vendors should assess whether this code truly reflects their product classification or whether broader pharmaceutical and OTC supply agreements represent a more realistic procurement vehicle for their business development strategy.